BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17686824)

  • 1. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
    Seike M; Yanaihara N; Bowman ED; Zanetti KA; Budhu A; Kumamoto K; Mechanic LE; Matsumoto S; Yokota J; Shibata T; Sugimura H; Gemma A; Kudoh S; Wang XW; Harris CC
    J Natl Cancer Inst; 2007 Aug; 99(16):1257-69. PubMed ID: 17686824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression signature predicts recurrence in lung adenocarcinoma.
    Larsen JE; Pavey SJ; Passmore LH; Bowman RV; Hayward NK; Fong KM
    Clin Cancer Res; 2007 May; 13(10):2946-54. PubMed ID: 17504995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic test for adenocarcinoma of the lung from gene expression profiling data.
    Gordon GJ; Richards WG; Sugarbaker DJ; Jaklitsch MT; Bueno R
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):905-10. PubMed ID: 14504202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.
    Raponi M; Zhang Y; Yu J; Chen G; Lee G; Taylor JM; Macdonald J; Thomas D; Moskaluk C; Wang Y; Beer DG
    Cancer Res; 2006 Aug; 66(15):7466-72. PubMed ID: 16885343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma.
    Guo L; Ma Y; Ward R; Castranova V; Shi X; Qian Y
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3344-54. PubMed ID: 16740756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
    Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
    J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor, node and metastasis classification of lung cancer--M1a versus M1b--analysis of M descriptors and other prognostic factors.
    Sánchez de Cos Escuín J; Abal Arca J; Melchor Íñiguez R; Miravet Sorribes L; Núñez Ares A; Hernández Hernández JR; García Arangüena L; Núñez Delgado M; Pavón Fernández MJ; Francisco Corral G; de Esteban Júlvez L; González Budiño MT; Abad Cavaco F; Ansótegui Barrera E; Andreo García F; Serra Mitjans M; Hernández Rodríguez H
    Lung Cancer; 2014 May; 84(2):182-9. PubMed ID: 24629637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma.
    Neri S; Ishii G; Taira T; Hishida T; Yoshida J; Nishimura M; Nagai K; Ochiai A
    Ann Surg Oncol; 2012 Nov; 19(12):3953-62. PubMed ID: 22669451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
    Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of number of metastatic lymph nodes and metastatic lymph node ratio on the prognosis in patients with adenocarcinoma of the esophagogastric junction after curative resection].
    Zhang H; Chen C; Yue J; Ma M; Ma Z; Yu Z
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):141-6. PubMed ID: 24796465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction.
    Endoh H; Tomida S; Yatabe Y; Konishi H; Osada H; Tajima K; Kuwano H; Takahashi T; Mitsudomi T
    J Clin Oncol; 2004 Mar; 22(5):811-9. PubMed ID: 14990636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profiling defines a recurrence signature in lung squamous cell carcinoma.
    Larsen JE; Pavey SJ; Passmore LH; Bowman R; Clarke BE; Hayward NK; Fong KM
    Carcinogenesis; 2007 Mar; 28(3):760-6. PubMed ID: 17082175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes.
    Alatengbaolide ; Lin D; Li Y; Xu H; Chen J; Wang B; Liu C; Lu P
    Am J Clin Oncol; 2013 Aug; 36(4):325-30. PubMed ID: 22547011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
    Yanagisawa K; Tomida S; Shimada Y; Yatabe Y; Mitsudomi T; Takahashi T
    J Natl Cancer Inst; 2007 Jun; 99(11):858-67. PubMed ID: 17551146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of lymph node metastasis by gene expression profiling in patients with primary resected lung cancer.
    Moriya Y; Iyoda A; Kasai Y; Sugimoto T; Hashida J; Nimura Y; Kato M; Takiguchi M; Fujisawa T; Seki N; Yoshino I
    Lung Cancer; 2009 Apr; 64(1):86-91. PubMed ID: 18930562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.
    Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH
    Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
    Zhang Z; Guo Y
    Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma.
    Meaney CL; Zingone A; Brown D; Yu Y; Cao L; Ryan BM
    Oncotarget; 2017 Jun; 8(25):40946-40957. PubMed ID: 28402963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.